A study conducted on patients with diabetes mellitus type 2 (DM type 2) using SGLT2 inhibitors or DPP-4 inhibitors revealed that the rate of acute pancreatitis was significantly decreased in patients taking SGLT2 inhibitors than in those taking DPP-4 inhibitors [76]. Here, SLC5A2 is linked to type 2 diabetes mellitus.